Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Unapproved or misbranded drugs

The product was marketed without an approved NDA/ANDA, or does not meet the OTC monograph it claims to follow. Nothing about the product - dose, purity, safety - has been reviewed by FDA, so the claims on the box are unverified.

309 FDA drug recalls with this cause, newest first.

Every prescription drug and most over-the-counter drugs sold in the US need either an approved application (an NDA or ANDA) or must fit an OTC monograph. A product that skips both is pulled regardless of whether anything is physically wrong with it, because its dose, purity and claims were never checked. Typical cases: compounded products sold at commercial scale, imported drugs not cleared for the US, and products whose labeling makes claims that turn them into unapproved new drugs. Supplements that turn out to contain a hidden prescription drug are filed under chemical contamination and hidden ingredients instead.

Class II · Moderate risk

My Way (levonorgestrel)

Marketed Without an Approved NDA/ANDA: 2-pack configuration did not receive appropriate regulatory approval prior to release.

Terminated Unapproved drug Lupin Pharmaceuticals Inc. D-0838-2018
Class II · Moderate risk

My Way (Levonorgestrel)

Marketed Without an Approved NDA/ANDA: 2-pack configuration did not receive appropriate regulatory approval prior to release.

Terminated Unapproved drug Lupin Pharmaceuticals Inc. D-0837-2018
Class I · High risk

Limbrel500

Marketed Without An Approved NDA/ANDA: Based on the labeling claims, these products are unapproved drugs for which the safety and efficacy have not been established and, therefore, subject to recall.

Terminated Unapproved drug Primus Pharmaceuticals, Inc. NDC 68040-606-16 D-0347-2018
Class I · High risk

Limbrel250

Marketed Without An Approved NDA/ANDA: Based on the labeling claims, these products are unapproved drugs for which the safety and efficacy have not been established and, therefore, subject to recall.

Terminated Unapproved drug Primus Pharmaceuticals, Inc. NDC 68040-605-16 D-0346-2018
Class I · High risk

Limbrel (flavocoxid 500 mg)

Marketed Without An Approved NDA/ANDA: Based on the labeling claims, these products are unapproved drugs for which the safety and efficacy have not been established and, therefore, subject to recall.

Terminated Unapproved drug Primus Pharmaceuticals, Inc. NDC 68040-602-16 D-0345-2018
Class I · High risk

Limbrel (flavocoxid 250 mg)

Marketed Without An Approved NDA/ANDA: Based on the labeling claims, these products are unapproved drugs for which the safety and efficacy have not been established and, therefore, subject to recall.

Terminated Unapproved drug Primus Pharmaceuticals, Inc. NDC 68040-601-16 D-0344-2018
Class II · Moderate risk

TAD Glutathione Whitening Kits lyophilized powder for injection

Marketed Without An Approved NDA/ANDA: Flawless Beauty, LLC is voluntarily recalling all lots of different products sold individually or as part of multi-unit kits in accordance with Consent Decree of Permanent Injunction ordered by the United States District Court due to misbranding and unapproved new drugs pursuant to the FD&C Act.

Terminated Unapproved drug Flawless Beauty LLC D-0335-2018
Class II · Moderate risk

Saluta Glutathione Whitening kits

Marketed Without An Approved NDA/ANDA: Flawless Beauty, LLC is voluntarily recalling all lots of different products sold individually or as part of multi-unit kits in accordance with Consent Decree of Permanent Injunction ordered by the United States District Court due to misbranding and unapproved new drugs pursuant to the FD&C Act.

Terminated Unapproved drug Flawless Beauty LLC D-0334-2018
Class II · Moderate risk

Ling Zhi capsules

Marketed Without An Approved NDA/ANDA: Flawless Beauty, LLC is voluntarily recalling all lots of different products sold individually or as part of multi-unit kits in accordance with Consent Decree of Permanent Injunction ordered by the United States District Court due to misbranding and unapproved new drugs pursuant to the FD&C Act.

Terminated Unapproved drug Flawless Beauty LLC D-0333-2018
Class II · Moderate risk

Sterilized water for injections BP

Marketed Without An Approved NDA/ANDA: Flawless Beauty, LLC is voluntarily recalling all lots of different products sold individually or as part of multi-unit kits in accordance with Consent Decree of Permanent Injunction ordered by the United States District Court due to misbranding and unapproved new drugs pursuant to the FD&C Act.

Terminated Unapproved drug Flawless Beauty LLC D-0332-2018
Class II · Moderate risk

TP Drug Laboratories Vitamin C ampules

Marketed Without An Approved NDA/ANDA: Flawless Beauty, LLC is voluntarily recalling all lots of different products sold individually or as part of multi-unit kits in accordance with Consent Decree of Permanent Injunction ordered by the United States District Court due to misbranding and unapproved new drugs pursuant to the FD&C Act.

Terminated Unapproved drug Flawless Beauty LLC D-0331-2018
Class II · Moderate risk

Reiki Glutathione Whitening kits

Marketed Without An Approved NDA/ANDA: Flawless Beauty, LLC is voluntarily recalling all lots of different products sold individually or as part of multi-unit kits in accordance with Consent Decree of Permanent Injunction ordered by the United States District Court due to misbranding and unapproved new drugs pursuant to the FD&C Act.

Terminated Unapproved drug Flawless Beauty LLC D-0330-2018
Class II · Moderate risk

Laennec INJ

Marketed Without An Approved NDA/ANDA: Flawless Beauty, LLC is voluntarily recalling all lots of different products sold individually or as part of multi-unit kits in accordance with Consent Decree of Permanent Injunction ordered by the United States District Court due to misbranding and unapproved new drugs pursuant to the FD&C Act.

Terminated Unapproved drug Flawless Beauty LLC D-0329-2018
Class II · Moderate risk

Tationil Glutathione

Marketed Without An Approved NDA/ANDA: Flawless Beauty, LLC is voluntarily recalling all lots of different products sold individually or as part of multi-unit kits in accordance with Consent Decree of Permanent Injunction ordered by the United States District Court due to misbranding and unapproved new drugs pursuant to the FD&C Act.

Terminated Unapproved drug Flawless Beauty LLC D-0328-2018
Class II · Moderate risk

Laroscorbine Platinum Vitamin C 1 gm Collagen 0.35 gm

Marketed Without An Approved NDA/ANDA: Flawless Beauty, LLC is voluntarily recalling all lots of different products sold individually or as part of multi-unit kits in accordance with Consent Decree of Permanent Injunction ordered by the United States District Court due to misbranding and unapproved new drugs pursuant to the FD&C Act.

Terminated Unapproved drug Flawless Beauty LLC D-0327-2018
Class II · Moderate risk

Tatiomax Gluatathione Whitening kits

Marketed Without An Approved NDA/ANDA: Flawless Beauty, LLC is voluntarily recalling all lots of different products sold individually or as part of multi-unit kits in accordance with Consent Decree of Permanent Injunction ordered by the United States District Court due to misbranding and unapproved new drugs pursuant to the FD&C Act.

Terminated Unapproved drug Flawless Beauty LLC D-0326-2018
Class II · Moderate risk

Relumins Vitamin C Solvent ampules

Marketed Without An Approved NDA/ANDA: Flawless Beauty, LLC is voluntarily recalling all lots of different products sold individually or as part of multi-unit kits in accordance with Consent Decree of Permanent Injunction ordered by the United States District Court due to misbranding and unapproved new drugs pursuant to the FD&C Act.

Terminated Unapproved drug Flawless Beauty LLC D-0325-2018
Class II · Moderate risk

Relumins Advanced Glutathione kits

Marketed Without An Approved NDA/ANDA: Flawless Beauty, LLC is voluntarily recalling all lots of different products sold individually or as part of multi-unit kits in accordance with Consent Decree of Permanent Injunction ordered by the United States District Court due to misbranding and unapproved new drugs pursuant to the FD&C Act.

Terminated Unapproved drug Flawless Beauty LLC D-0324-2018
Class III · Low risk

Gabapentin Oral Solution

CGMP Deviations: Inadvertent release of a drug product with unapproved active ingredient manufacturer.

Terminated Unapproved drug Akorn Inc D-0211-2018
Class III · Low risk

Meclizine hydrochloride tablets USP

Marketed without an approved NDA/ANDA: Bottles were released prior to final approval.

Terminated Unapproved drug Jubilant Cadista Pharmaceuticals, Inc. NDC 59746-122-06 D-0082-2018